(
A, B) RT-qPCR quantification of the change in total (
A) and 4sU-labeled (
B) RNA levels in HCT116 cells treated with the indicated siRNAs upon 2 hr TRAIL treatment (
n = 4). Fold changes were calculated from C
t values normalized to
18S rRNA. (
C) Chromatin immunoprecipitation (ChIP)-qPCR was used to measure the change in hypophosorylated RNAPII occupancy at the indicated promoters in cells nucleofected with the indicated siRNAs (
n = 4). Mouse IgG antibody was included in parallel immunoprecipitation reactions with chromatin from scramble siRNA-treated non-apoptotic cells in lieu of RNAPII antibody as a control. (
D) Representative western blots on lysates of HCT116 cells depleted of either 3’ DFs (DIS3L2, EXOSC4, and PNPT1) or XRN1 before and after 2 hr TRAIL treatment, probing for the indicated protein or RPB1 C-terminal domain (CTD) phosphorylation state. Apoptosis induction was confirmed by observing CASP3 cleavage. A vinculin (VCL) loading control was imaged for the blots of each phosphorylation state, but a single representative panel is shown. Quantification of RPB1 phosphorylation states from four replicates displayed in
Figure 4F. (
E) Band intensity fold changes of hypophosphorylated RPB1 and TBP derived from four biological replicates of the experiment described in (
D). Bar graph displays mean ± SEM with individual biological replicates represented as dots. Statistically significant deviation from a null hypothesis of 1 was determined using one sample t test and indicated with asterisks directly above bars, while student’s t tests with the Holm-Sidak correction for multiple comparisons were performed to compare mean values between groups indicated with brackets. *p<0.05, **p<0.00.1, ***p<0.001.